Views & Analysis Addressing MS’ two-tier healthcare system is about ‘social j... NICE has reversed its decision not to approve a new drug that offers hope to thousands o
Views & Analysis Listening to the Patient Voice: seek out the quietest voice ... The success or failure of patient centricity rests on getting the patient voice in the mix – not just listening to those who shout the loudest.
Views & Analysis Case study: Ensuring safety by digitally linking prescriptio... Monitoring people who are on disease modifying drugs (DMDs) is paramount to providing safe, high-quality MS care.
Views & Analysis Addressing the growing need for better Multiple Sclerosis ca... Jo Sopala of the MS Trust describes the organisation's work in creating better multiple sclerosis care.
News Gilead's twice-yearly PrEP drug is cleared by FDA Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
